Skip to content
Screener

Assembly Biosciences ASMB Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue$9.6MBeat by $301.8K
EPS-$1.33Miss by $0.68
Revenue estimate$9.3M
EPS estimate-$0.65

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$9.1M
EPS estimate-$0.66

Financials

Q2 2025

Income statement

See full
Revenue$9.6M+12.8%
Operating income-$11.1M+9.1%
Net income-$10.2M+8.6%
EPS (diluted)-$1.33+32.8%

Balance sheet

See full
Cash & equivalents$24.0M+25.0%
Total debt$2.9M+65.2%
Total equity$18.1M-47.8%
Total assets$80.8M-30.0%

Cash flow

See full
Operating cash flow-$16.8M+2.0%
CapEx--100%
Free cash flow-$16.8M+2.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$131.37M+50.9%
Enterprise value$110.24M+58.4%
P/S4×-0.1×

Profitability

See full
Operating margin-130.9%-40.2pp
Net margin-117.2%-36.3pp
FCF margin-168%-280pp

Returns & leverage

See full
Return on equity-147.6%+121pp
Debt / equity0.2×+0.1×
Current ratio1.6×-1.1×

FAQ

When did Assembly Biosciences report Q2 2025 earnings?
Assembly Biosciences (ASMB) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Assembly Biosciences's Q2 2025 revenue and EPS?
Assembly Biosciences reported revenue of $9.6M and eps of $-1.33 for Q2 2025.
Did Assembly Biosciences beat estimates in Q2 2025?
Revenue beat the consensus estimate of $9.3M by $301.8K. EPS missed the consensus estimate of $-0.65 by $0.68.
How did Assembly Biosciences's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.8% from $8.5M a year earlier and eps grew 32.8% from $-1.98.
Where can I find Assembly Biosciences's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-104020) and the 10-Q periodic report (0000950170-25-104060) directly on SEC EDGAR. The filing index links above go to sec.gov.